Sunday, 31 August 2008
PolyMedix Initiates Dosing In Phase I Clinical Study Of Novel Systemic Antibiotic Compound
This first Phase I clinical trial testament assess the safety of PMX-30063. The protocol for the trial involves a dose-escalation written report in healthy volunteers in which each subject testament receive a single dose of PMX-30063. The subjects are grouped into different cohorts with different dosage levels which will admit for the study of the effects of increased dosages. PolyMedix expects to enroll a total of thirty to fifty subjects in this clinical tribulation. Upon successful completion of the first-class honours degree clinical subject area, PolyMedix plans to initiate a second clinical trial run to mimic the expected clinical dosing regimen. The second run, also to be conducted in healthy volunteers, will involve iterate dosing of two endovenous infusions per day, for up fourteen days. Following these clinical trials, meaning additional clinical studies and regulatory submissions will be required to obtain regulative approval from the FDA and other regulatory bodies before PMX-30063 could be commercially sold.
"The commence of the clinical survey for PMX-30063 represents a major milestone for PolyMedix, and we believe, for the full medical community of interests," said Nicholas Landekic, CEO of PolyMedix. "This novel antibiotic combine signals a fundamental potential breakthrough in treating infectious diseases. PMX-30063 is the first and only modest molecule defensin mimetic to commence clinical development for the treatment of systemic infections, and the first and solely such compound whose mechanism of action mechanism is intended to straight address the major problem of bacterial drug resistance. We ar proud to be the first troupe to bring this completely new type of antibiotic drug to clinical trials, and to address a major clinical want and market opportunity."
About PMX-30063
Completely different from other antibiotic drug compounds currently on the market, PMX-30063 is a synthetic chemical mimic of host united States Department of Defense proteins, one of the oldest and most in force antimicrobial defense systems ground in well-nigh all living creatures. PMX-30063 is the first little molecule mimetic of host defense proteins to embark clinical trials intended to treat systemic infections.
PolyMedix has undertaken in vivo studies in animals and in vitro pre-clinical studies to observe compound efficacy and toxicology attributes, and to judge the development of drug resistance. Based on these pre-clinical studies, we believe PMX-30063 has unique properties which sets it apart from traditional antimicrobial molecules and materials, including:
- A novel mechanism of action, the aim biophysical disruption of bacterial cell membranes, that makes development of bacterial resistance unlikely;
- Activity against both Gram-positive and Gram- minus bacteria, and in especial, activity against 146 dissimilar strains of Staphylococcus bacterium, including 89 drug-resistant strains of Staph bacteria;
- Bactericidal activity, meaning it kills bacteria directly, rather than simply stopping reproduction (bacteriostatic) as do many current antibiotics;
- Faster acting than many antibiotics; and
- Activity against drug-resistant bacteria, including clinical isolates of multiple vancomycin- and methicillin-resistant strains.
Primitive life sentence forms, such as molds, secrete compounds like penicillin to protect themselves from bacteria. This forms the basis for conventional antibiotics - compounds which act against biochemical targets or pathways in bacterial cells. Multi-cellular organisms, such as insects, animals, and human race, possess a more complex, first-line immune system defence against bacterial infections: the host defence proteins. Host defense proteins are part of the non-humoral (that is, not involving antibodies) response that keep world from speedily succumbing to infections. Biologists have observed many different classes of natural host-defense peptides. Although these molecules possess a diverse array of structures, their physicochemical properties ar similar. All are amphiphilic, meaning they have a combination of positively electrically charged properties, and hydrophobic (water-hating, fat-loving) chemical properties. This amphiphilic structure is believed to be responsible for horde defense peptides' antimicrobial activity and their unique abilities to straight disrupt bacterial cell membranes. Among the most vulgar and well-studied antimicrobial peptides are the defensins, establish in human beings, the magainins, found in frogs, and the cecropins and melitins, found in insects.
PMX-30063 is designed to mimicker the amphiphilic structure of the host defense proteins, but with a completely synthetic, non-peptide, small corpuscle structure. PMX-30063 directly disrupts bacterial electric cell membranes; a mechanism shared with the host defence proteins just is unique among known antibiotic drugs. For this reason, we believe that bacterial opposition is less likely to develop with PMX-30063 than has been experienced with many conventional antibiotic drugs. Multiple serial passage experiments conducted by PolyMedix and others on PMX-30063 and related PolyMedix antibiotic compounds also support our view of a lower likeliness of developing resistance.
About PolyMedix, Inc.
PolyMedix is a publicly traded biotechnology company focused on the development of novel drugs and biomaterials for the treatment of infectious diseases and sharp cardiovascular disorders. PolyMedix's compounds are based on biomimetics: non-peptide small molecule drugs that mimic the activity of proteins. The Company's antibiotic compounds, including PMX-30063 - small molecule mimetics of human host-defense proteins - have a wholly different mechanism of activity from stream antibiotic drugs, a mechanism which is intended to make bacterial resistance improbable to develop. These compounds are organism developed as rapidly performing antibiotics for serious systemic and local infections. The Company plans to go on the development of polymeric formulations as antimicrobial biomaterials, which canful be used as additives to paints, plastics, and textiles to create self-sterilizing products and surfaces. The Company's heptagonist compounds, including PMX-60056, reverse the activity of both heparin and Low Molecular Weight Heparins, with the goal of developing an antagonist drug that is safer and easier to use than currently sanctioned therapy. For more information, please visit PolyMedix on its web site at hTTP://www.polymedix.com.
This press release contains advanced statements made pursuant to the good harbor victuals of the Private Securities Litigation Reform Act of 1995 that involve risks and that could reason PolyMedix's actual results and experience to differ materially from awaited results and expectations expressed in these forward looking for statements. PolyMedix has in some cases identified forward-looking statements by using language such as "anticipates," "believes," "hopes," "estimates," "looks," "expects," "plans," "intends" and similar expression.. Among other things, there can buoy be no assurance that PolyMedix's compounds will enter or successfully complete clinical testing or be given regulatory approval to be sold and marketed in the Unites States or elsewhere. A more complete description of these risks, uncertainties and assumptions is included in PolyMedix's filings with the Securities and Exchange Commission. You should t stead undue reliance on any forward-looking statements. PolyMedix undertakes no duty to release publicly the results of any revisions to any such innovative statements that may be made to reflect events or luck after the date of this crusade release or to reflect the occurrence of unforeseen events.
PolyMedix, Inc.
More information
Monday, 11 August 2008
Blige Sued In Song Row
R+B star MARY J. BLIGE has been accused of theft songs from a California hip-hop tag in a new cause filed on Wednesday (06Aug08).
Drama Family Entertainment bosses claim Blige's hit single Work That was taken from their catalogue of songs.
It is alleged they hired producer Theron Feemster to record hits for their own artists - only instead he gave tracks to Blige.
The production company and record label executives claim Feemster's sung Pull 1 Rough, created during his time with Drama Family, very closely resembles Blige's single from her 2007 album Growing Pains - featured in an Apple iPod commercial-grade.
The company's lawyer Brian Caplan adds, "The music is identical."
The singer's bosses at Interscope Geffen - which has besides been named in the suit - have refused to remark, insisting they never discourse pending litigation.
Lawyers for Blige and Feemster did not return calls for comment.
More information
Wednesday, 6 August 2008
The Latest On Premier Science In Medical Oncology At The 33rd ESMO Congress, Stockholm, Sweden, Sept. 12-16, 2008
Some of the highlights that will be presented during the educational and scientific program at Europe's prime minister medical oncology meeting include:
Molecular analysis for target discovery: Identification of 'Achilles' heel'
MicroRNa, SiRNA libraries
Protein array
Innovation in titty cancer
Modulation of resistance to anti-Her2 therapies
Evaluation of prognostic markers on circulating tumour cells
New targets for three-bagger negative tumors
Stem cell as a potency target
Tools in daily clinical practice to improve treatment
Tailoring therapy in lung cancer
Medical implications of resistance to EGFR
Personalized cancer therapies for non-EGFR receptor-dependent tumors
New pathways in targeted therapy
IGF-1, PI 3, PARP, Met
Optimal integration of newer agents in the treatment of advanced CRC
Genomic and pharmacogenetic markers for treatment decision
Upfront serial vs. combination chemotherapy
Renal cell cancer
VEGF biology and resistance
mTOR
Tackling future issues
Hitting the cell in ovarian and endometrial cancers
PARP, mTOR, etc
Head and neck cancer
Viruses: Prevention and therapy
Innovations in radiation oncology (IMRT and look-alike guided radiotherapy)
How to integrate EGFR inhibitors and beyond
Hematological malignancies
The role of high-dose therapy and allografting stemcell transplanting in the era of '-nibs' and '-mabs'
Communication skills in advanced crab care
o The use of communication skills: Lessons derived from microanalytical studies
Advances in soft tissue sarcoma, GIST and beyond
GIST - the role of adjuvant therapy and mutational analysis in treatment decision-making
Molecular biology and targeted therapy of sarcomas
Hyperthermia improves local control of STS - where future?
Emerging therapies for rare tumors
Neuroendocrine tumors, HCC, thyroid cancer, papillary RCC
Assessing, reporting and managing the safety of cancer drugs
Detecting safety signals
The function of pharmacogenetics in predicting and managing toxicity
Handling side effects of targeted therapies
Integration of targeted therapies with radiation
Where we are with radiation modifiers?
Unplanned analysis of molecular studies
Harmful or safe?
Cancer patients
o Should all receive prophylactically antithrombotic therapy?
o Dealing with hard cases in daily clinical practice
New developments in myeloma
Prognostic factors and the role of novel drugs
The status of transplantation
Glioma
From tomography to management
Recent progress in immunotherapy
Anti cancer vaccines
Combining immunotherapy with classical antineoplastic therapy
Advanced prostate genus Cancer
The ever-changing face of hormonal therapy
Diabetes and cardiovascular disease in prostate cancer survivors
Latest on oncology in developing countries
Cancer encumbrance and the role of prevention
Balancing costs and benefits in malignant neoplastic disease therapy and prevention
Drug development
How to recognize a promising drug: The role of clinical and biologic endpoints
The persona of regulatory bodies in the do drugs approval process
The Highlights of the day session: summary roger Huntington Sessions of topics from the preceding day aiming to give an overview of the to the highest degree interesting and important points to emerge from previous sessions.
Late-breaking abstracts: oral roger Huntington Sessions to represent latest research studies with new research findings
Controversy roger Sessions will make lively discussions on hot topics.
The seventh ESMO Patient Seminar where patients will have the chance to meet oncologists and hear about the conditions of cancer treatment in Europe, comparing conditions in Eastern and Western countries; discuss and face up doctors around the consequences of cancer the Crab therapy, instruct the approaches to long-term survivorship and the next perspective of cancer treatments
Numerous Educational Sessions to submit state-of-the-art oncology.
The fifth slew of ESMO Designated Centers of Integrated Oncology and Palliative Care will be announced as centers of excellence for patient precaution in Europe.
A session on ESMO Clinical Recommendations will update current ESMO Guidelines on clinical practice for various tumour types.
Oncology Highlights of the most significant advances in cancer handling in 2008.
And� Her Majesty Queen Silvia of Sweden accepted to be the Patron of the thirty-third ESMO Congress and will give the welcome address during the Opening Ceremony
Meeting venue
The 33rd ESMO Congress will take place at the Stockholm International Fairs in �lvsj� (M�ssv�gen 1, SE-12580 Stockholm-�lvsj� located a short train journey from Stockholm Central Station.
The conference full broadcast is usable at http://www.esmo.org/activities/esmocongress/stockholm08/program_cng/
Accomodation
Congrex Sweden AB has been appointed by ESMO to manage hotel accommodation in relation to the thirty-third ESMO Congress For hotel reservation, please visit: http://www.esmo.org/activities/esmocongress/stockholm08/accommodation_cng/
About the European Society for Medical Oncology (ESMO)
The European Society for Medical Oncology (ESMO) is the leading European not-for-profit, professional organisation for medical oncology promoting multidisciplinary malignant neoplastic disease treatment around the world.
ESMO unites aesculapian oncologists and other oncology specialists, healthcare professionals, caregivers, patients, policy-makers and all the key stakeholders in a world-wide alliance committed to eradicating cancer and ensuring equal access to high quality treatment for all patients. Through state of the art education and training programs, ESMO plays an subservient role in providing the oncology community with the most up-to-date scientific research and information available. ESMO is dedicated to educating and supporting oncologists, optimizing patient guardianship, disseminating cancer-specific information to the public, and advocating patient rights. As an authoritative part in the fight against cancer, ESMO provides both the platform and the consultative expertise to influence national and international organizations as well as European authorities, in order to establish common standards for a multidisciplinary approach to cancer treatment. Through its flagship daybook, Annals of Oncology, ESMO publishes articles on all aspects of clinical oncology.
To find kO'd more about ESMO please visit hTTP://www.esmo.org/
Source: Vanessa Pavinato
European Society for Medical Oncology
More info
- Swiss HIV/AIDS Statement Could Have Serious Ramifications
- CMS Allocating $49M To High-Risk Health Insurance Pools In 31 States
- Survival Advantage Discovered In Mutant Testis Cells Behind Genetic Disorder
- Protecting The Hearts Of Patients With Muscular Dystrophy Using New Approach
- Preregistration Trainee Pharmacist Training Programme 2008/2009 - National Pharmacy Association, UK
Wednesday, 25 June 2008
Lunaris
Artist: Lunaris
Genre(s):
Metal: Death,Black
Rock: Sympho
Discography:
Cyclic
Year: 2004
Tracks: 11
...The Infinite
Year: 2002
Tracks: 10
 
"Sex" sells at theaters in America, Europe
Thursday, 12 June 2008
Babyshambles Drummer To Release Solo Single
Babyshambles drummer Adam Ficek is concentrating on a new solo offshoot named Roses, Kings, Castles and later this month he'll be releasing his first single.
Writing on MySpace, Ficek says of the project: "The music: a cobblestone bridge lying somewhere between the pastoral warmth of Belle & Sebastian and the suburban, quixotic pop of Syd Barrett."
His first release will be a split limited edition 7" with Hideki Kaji, released on June 16th by Alphaville Records. Ficek offers the track 'Sparkling Bootz' and Hideki Kaji gives 'Typical Me, Typical You'.
Speaking further on the new act, the sticksman has revealed he hopes to attract a different fanbase to the one his shambolic other band already has.
"I'm hoping to get a new audience," says Ficek. "A lot of Babyshambles fans are leather jacket / Jack Daniel's rock n' roll fans."
"I'm not like that. I could pretend to be swaggering around with a cigarette hanging out of my mouth, but what's the point in doing that?"
Four songs from Roses, Kings, Castles are on MySpace for listening right now - 'Sparkling Bootz', 'Entroubled', 'Tales To Tell' and 'Sweet Contempt'.
See Also
Friday, 6 June 2008
Caught Live: The Raconteurs
a gig.
And there’s nothing more special than THE RACONTEURS when they’re
in full majestic flow.
The ROLLING STONES Lords watched JACK WHITE and his gang lay
waste to London’s Hammersmith Apollo with a mesmerising display of rock n
roll virtuosity.
There’s truly no better live act in action on the planet at the moment.
While THE WHITE STRIPES can rightful lay claim to having cornered the
market in clattering, primal blues-rock, The Raconteurs offer so much more.
There’s swampy country rock - Carolina Drama, turbo-charged power pop – Steady
As She Goes and blistering hard rock - Your Blue Veins.
While Jack teases solos of unimaginable complexity out of his axe co-vocalist BRENDAN
BENSON acts as a trusty foil.
Bassist JACK LAWRENCE provides a resoundingly powerful underpinning to
proceedings and drummer PATRICK KEELER thrashes his kit like KEITH
MOON.
The quartet, ably abetted by a new keyboard player, re-package and re-wire the
past fifty years of amplified guitar music and the results are nothing short
of spectacular.
It's only rock and roll. But you'd be deranged not to like it.
Thursday, 29 May 2008
N.Phect
Artist: N.Phect
Genre(s):
Drum & Bass
Discography:
Punchline DD
Year: 2005
Tracks: 1
Oliver making cookery show for kids